Literature DB >> 23740572

Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.

Guillaume Lefèvre1, Luc Dauchet, Eric Hachulla, David Montani, Vincent Sobanski, Marc Lambert, Pierre-Yves Hatron, Marc Humbert, David Launay.   

Abstract

OBJECTIVE: Pulmonary hypertension (PH) is a frequent and life-limiting complication of systemic sclerosis (SSc). However, data on survival rates and their evolution over time, as well as prognostic factors in SSc complicated by PH, are still conflicting. The aim of this study was to conduct a systematic review and meta-analysis of cohort studies to assess pooled survival and prognostic factors for survival in patients with SSc-associated PH.
METHODS: For this systematic review and meta-analysis, we searched the Medline and EMBase databases (January 1960 to January 2012). All cohort studies in which survival and/or prognostic factors for SSc-associated PH were reported were included in the analysis. We calculated the pooled survival rates and analyzed their evolution over time and identified prognostic factors for survival.
RESULTS: Twenty-two studies were included, representing a total of 2,244 patients with SSc-associated PH. The pooled 1-, 2-, and 3-year survival rates were 81% (95% confidence interval [95% CI] 79-84%), 64% (95% CI 59-69%), and 52% (95% CI 47-58%), respectively. Meta-regression did not reveal a significant change in survival over time, while baseline hemodynamic measures of PH severity were significantly correlated with survival. In patients with SSc complicated by pulmonary arterial hypertension (PAH), age, male sex, diffusing capacity for carbon monoxide (DLCO), pericardial effusion, and the parameters classically associated with the severity of idiopathic PAH, including the 6-minute walk distance, mean pulmonary artery pressure, cardiac index, and right atrial pressure, were significant prognostic factors. DLCO and pericardial effusion were the only prognostic factors in patients with interstitial lung disease-related PH.
CONCLUSION: Our meta-analysis revealed a poor pooled 3-year survival rate of 52% in patients with SSc-associated PH. Baseline hemodynamic measures of PAH severity, but not the period of time during which patients were included in the studies, correlated significantly with survival in patients with SSc-associated PAH. All of the prognostic factors typically observed in idiopathic PAH, including the 6-minute walk distance and right atrial pressure, were also prognostic factors in SSc-associated PAH.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23740572     DOI: 10.1002/art.38029

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  59 in total

1.  Independence Day: Separating Right Ventricular Function From Pulmonary Arterial Hypertension in Systemic Sclerosis.

Authors:  Bradley A Maron
Journal:  Circulation       Date:  2016-05-11       Impact factor: 29.690

Review 2.  Scleroderma-related lung disease: are adipokines involved pathogenically?

Authors:  Shannon Haley; Dilip Shah; Freddy Romero; Ross Summer
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

Review 3.  Personalized medicine in systemic sclerosis: facts and promises.

Authors:  Rucsandra Dobrota; Carina Mihai; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

4.  Systemic sclerosis: Choosing patients wisely when treating interstitial lung disease.

Authors:  Richard M Silver
Journal:  Nat Rev Rheumatol       Date:  2017-07-06       Impact factor: 20.543

5.  Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.

Authors:  Vivek Nagaraja; Marco Matucci-Cerinic; Daniel E Furst; Masataka Kuwana; Yannick Allanore; Christopher P Denton; Ganesh Raghu; Vallerie Mclaughlin; Panduranga S Rao; James R Seibold; John D Pauling; Michael L Whitfield; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2020-05-18       Impact factor: 10.995

6.  Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.

Authors:  Rennie L Rhee; Nicole B Gabler; Sapna Sangani; Amy Praestgaard; Peter A Merkel; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

7.  Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Zeling Cao; Stephen C Mathai; Laura K Hummers; Ami A Shah; Fredrick M Wigley; Noah Lechtzin; Paul M Hassoun; Reda E Girgis
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

8.  Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?

Authors:  Ziwei Liu; Jieying Wang; Jinzhi Lai; Qian Wang; Jiuliang Zhao; Can Huang; Xiaoxi Yang; Junyan Qian; Hui Wang; Xiaoxiao Guo; Yongtai Liu; Zhuang Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2018-07-24       Impact factor: 2.980

9.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

Review 10.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.